Search

Your search keyword '"Philippe Reix"' showing total 175 results

Search Constraints

Start Over You searched for: Author "Philippe Reix" Remove constraint Author: "Philippe Reix"
175 results on '"Philippe Reix"'

Search Results

2. Whole pulmonary assessment 1 year after paediatric acute respiratory distress syndrome: prospective multicentre study

3. Diffuse alveolar haemorrhage in children: an international multicentre study

4. Viral respiratory tract infections in young children with cystic fibrosis: a prospective full-year seasonal study

5. Implementation of Model-Based Dose Adjustment of Tobramycin in Adult Patients with Cystic Fibrosis

6. Chest physiotherapy enhances detection of Pseudomonas aeruginosa in nonexpectorating children with cystic fibrosis

7. Impact of Coexistence Phenotype Between Staphylococcus aureus and Pseudomonas aeruginosa Isolates on Clinical Outcomes Among Cystic Fibrosis Patients

8. Pulmonary hemosiderosis in children with Down syndrome: a national experience

9. Lumacaftor/ivacaftor initiation in two liver transplantation patients under tacrolimus and antifungal azoles

10. Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one

11. Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part three

12. Strong incidence of Pseudomonas aeruginosa on bacterial rrs and ITS genetic structures of cystic fibrosis sputa.

13. Optimized approach for the identification of highly efficient correctors of nonsense mutations in human diseases.

14. Moving the Dial on Airway Inflammation in Response to Trikafta in Adolescents with Cystic Fibrosis

15. Auteurs de la 5e édition

16. Use of 2,6-diaminopurine as a potent suppressor of UGA premature stop codons in cystic fibrosis

17. Dépistage des anomalies de la tolérance au glucose et du diabète de mucoviscidose. Position de la Société française de la mucoviscidose (SFM), de la Société francophone du diabète (SFD) et de la Société française d’endocrinologie et diabétologie pédiatrique (SFEDP)

18. Profiling the response to lumacaftor-ivacaftor in children with cystic between fibrosis and new insight from a French-Italian real-life cohort

19. Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for

20. The U UGA C sequence provides a favorable context to ELX-02 induced CFTR readthrough

21. Human Papilloma Virus Vaccination Among Female Patients Attending French Pediatric Cystic Fibrosis Centers

22. Screening strategies for glucose tolerance abnormalities and diabetes in people with cystic fibrosis

23. Rescue of Pap-Mas in Systemic JIA Using Janus Kinase Inhibitors, Case Report and Systematic Review

24. A formalized transition program for cystic fibrosis: A 10‐year retrospective analysis of 97 patients in Lyon

25. Tobramycin Therapeutic Drug Monitoring in Adult patients with Cystic Fibrosis: Clinical-Based Empiric Dosing versus Model-Informed Precision Dosing

26. Risk factors for nontuberculous mycobacterial isolation in patients with cystic fibrosis: A meta‐analysis

27. French national cohort of neuroendocrine cell hyperplasia of infancy (FRENCHI) study: diagnosis and initial management

28. Cumulative Incidence and Risk Factors for Severe COVID-19 in French People with Cystic Fibrosis

29. Diffuse alveolar haemorrhage in children: an international multicentre study

30. Population Pharmacokinetic Modeling and Dosing Simulations of Tobramycin in Pediatric Patients with Cystic Fibrosis

31. Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study

32. Using chest CT scan and unsupervised machine learning for predicting and evaluating response to lumacaftor-ivacaftor in people with cystic fibrosis

33. Factors Associated with Asthma Severity in Children: Data from the French COBRAPed Cohort

34. Azole resistance in Aspergillus fumigatus isolates from respiratory specimens in Lyon University Hospitals, France: prevalence and mechanisms involved

35. Real-world assessment of LCI following lumacaftor-ivacaftor initiation in adolescents and adults with cystic fibrosis

36. Chest physiotherapy enhances detection of Pseudomonas aeruginosa in nonexpectorating children with cystic fibrosis

37. HOMA indices as screening tests for cystic fibrosis-related diabetes

38. Chest physiotherapy enhances detection of

40. Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function

41. Real-life acute lung function changes after lumacaftor/ivacaftor first administration in pediatric patients with cystic fibrosis

42. Palivizumab prophylaxis in infants with cystic fibrosis does not delay first isolation of Pseudomonas aeruginosa or Staphylococcus aureus

43. Actinomycose disséminée traitée par clindamycine

44. WS15.3 HOMA indexes diagnosis performance for Cystic Fibrosis-Related Diabetes

45. Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis

47. Health-related quality of life in children interstitial lung disease

48. Viral respiratory tract infections in young children with cystic fibrosis: a prospective full-year seasonal study

49. Usefulness of bronchoalveolar lavage in a French pediatric cohort with hypersensitivity pneumonitis

50. Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis

Catalog

Books, media, physical & digital resources